Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
59
resultados
Última actualización
15/12/2025 [06:45:00]
Resumen de: WO2025255419A1
Provided are methods for inducing apoptosis of cells. The cells may be cancer cells (e.g., lymphoma cells). The cancer cells may be resistant to other known therapies, such as, for example, therapy with rituximab, a chimeric anti-CD20 monoclonal antibody. A method can include contacting the cells with a compound having the following structure: (MMRi36).
Resumen de: WO2025255297A1
The disclosure provides binding agents (e.g., antibodies) against human TIGIT, as well as kits and methods for using the same (e.g., immunoassays) as part of a companion diagnostic and for other applications. In some aspects, the binding agents described herein may be used in assays for detecting ovarian cancer, squamous cell carcinoma of the head and/or neck, non-small cell lung cancer, cervical cancer, esophageal cancer, melanoma, breast cancer, hepatocellular cancer, colorectal cancer, gastric cancer, renal cell carcinoma, prostate cancer, pancreatic cancer, bladder cancer, lymphoma, metastatic cancer, and/or a solid tumor in, on, or derived from any human tissue or organ.
Resumen de: WO2025253079A1
The present invention relates to a novel anti-HLA-DR IgM isotype monoclonal antibody and to the use thereof alone or in addition to anti-CD20 IgG1 or IgM isotype antibodies, in the treatment of B-phenotype lymphoid hemopathies, and in particular of non-Hodgkin lymphoma B, chronic lymphocytic leukemia (CLL) and B-cell malignant lymphoid hemopathies in general.
Resumen de: US2025376679A1
The invention relates to the inhibition of expression of interferon regulatory factor-4 (IRF4) using RNA interference, chemically-modified oligonucleotides, and/or chimeric siRNA multivalent combinations. The invention further relates to methods of treating IRF4 related conditions such as multiple myeloma.
Resumen de: US2025375450A1
The present disclosure is concerned with substituted quinazoline-2,4-diamines and compositions for the treatment of disorders associated with altered expression of SMARCA2 and/or SMARCA4 such as, for example, cancer (e.g., sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, gliomas, leukemia, lymphoma, chronic myeloproliferative disorders, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, plasma cell neoplasm (myeloma)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Resumen de: US2025375442A1
The present disclosure provides methods for treating leukemia (e.g., AML) using a CLK/DYRK inhibitor and a B-cell lymphoma 2 (BCL2) inhibitor (e.g., venetoclax). Kits for use in practicing the methods are also provided.
Resumen de: US2025375522A1
The invention is related to a chimeric checkpoint receptor (CCR) fusion protein, a nucleic acid molecule encoding said fusion protein, a vector comprising said nucleic acid molecule, a host cell comprising said nucleic acid molecule and/or expressing the fusion protein, a method for providing said host cell, a pharmaceutical composition comprising said fusion protein, nucleic acid molecule or host cell, and said products for use as a medicament and in the treatment of B cell lymphoma.
Resumen de: US2025375524A1
Provided herein are methods for treatment and uses involving dosing of compositions containing NK cells deficient in expression of FcRγ chain (g-NK cells) engineered with a recombinant chimeric antigen receptor (CAR) in combination with a monoclonal antibody. Among the provided methods and uses are methods and uses for treating cancer, such as multiple myeloma or lymphoma.
Resumen de: WO2025254458A1
The present invention relates to a novel proteasome inhibitor comprising a digoxigenin-derived lactone ring-based compound as an active ingredient, and can simultaneously exhibit high 20S proteasome inhibitory activity and low normal cell toxicity. The compound has excellent cancer cell selectivity, has pharmacological properties with improved anticancer effects and therapeutic indices, and can be useful for various carcinomas such as multiple myeloma, breast cancer, and hepatocellular carcinoma.
Resumen de: WO2025248500A1
The present invention relates to antibodies that bind to ENPP3 and antibody-drug conjugates comprising an antibody that binds to ENPP3 conjugated to a drug, such as an auristatin. Also provided herein are methods for treating a solid tumor or leukemia comprising administering such ADCs.
Resumen de: AU2024258892A1
The present invention relates to combinations comprising a therapeutically effective amount of a menin-mixed-lineage leukemia 1 (menin-MLL) inhibitor; and a therapeutically effective amount of a DNA intercalating agent and a pyrimidine analog; as well as to methods for treating a subject diagnosed with cancer using such combinations.
Resumen de: AU2024257254A1
Embodiments of the present invention relate to methods of treating multiple myeloma in a subject in need thereof comprising administering to the subject a BCMAxCD3 bispecific antibody on a bi-weekly dosing schedule.
Resumen de: US2025372262A1
Disclosed herein, in certain embodiments, are systems and methods of detecting the presence of a skin condition using a machine learning model based on molecular risk factors. In some instances, the skin condition is cancer, such as cutaneous T cell lymphoma (CTCL). In some cases, the skin cancer can be mycosis fungoides (MF) or Sézary syndrome (SS).
Resumen de: WO2025250667A1
The present disclosure relates to RIPK2 inhibitors of the formulae (I) or (II) for the treatment of e.g. inflammatory diseases, autoimmune diseases, granulomatous disease, neurodegenerative diseases or cancer, and, more specifically, for the treatment of inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, rheumatoid arthritis, inflammatory arthritis, peritonitis, ischemia reperfusion injury in kidney transplant, non-alcohol steatohepatitis, alcohol steatohepatitis, insulin-resistant type 2 diabetes, allergic rhinitis, asthma, atopic dermatitis, Sjogren's syndrome, spondyloarthritis, ankylosing spondylitis, pemphigus vulgaris, idiopathic plasmacytic lymphadenopathy, atherosclerosis, myocardial infarction, thrombosis, alpha-synucleinopathy, Parkinson's disease, dementia with Lewy body, multiple system atrophy, Alzheimer's disease, amyotrophic lateral sclerosis, and chronic obstructive pulmonary disease.
Resumen de: US2025368712A1
Provided are methods of treating cancer (e.g., non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), HER2-positive gastric/gastroesophageal junction (GEJ) cancer, de novo or transformed diffuse large B cell lymphoma (DLBCL), or indolent lymphoma) in an individual that comprise administering to the individual (a) a polypeptide comprising a SIRPα D1 domain variant and an Fc domain variant, and (b) an anti-cancer antibody (e.g., an anti-PD1 antibody, anti-HER2 antibody, or an anti-CD20 antibody). Also provided are related kits pharmaceutical compositions.
Resumen de: US2025368648A1
Some embodiments of the disclosure include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the inventive IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.
Resumen de: WO2025248072A1
The invention provides an antibody-drug conjugate comprising an anti-HER3 antibody or fragment thereof linked to a TOPO1 inhibitor drug via a linker unit, for use in treating a cancer selected from the group consisting of brain tumour, lung cancer, bladder cancer, stomach cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, liver cancer, kidney cancer, urothelial cancer, epidermal cancer, non-Hodgkin lymphoma, central nervous system tumour, or thyroid cancer; wherein the use comprises administering the antibody-drug conjugate or pharmaceutically acceptable salt thereof to a patient at a dose in the ranges as defined herein. Specific antibody-drug conjugates for use in treating breast cancer are also provided.
Resumen de: AU2024257950A1
Embodiments of the present invention relate to methods of treating multiple myeloma in a subject in need thereof, comprising administering therapeutically effective amounts of a BCMAxCD3 bispecific antibody and a GPRC5DxCD3 bispecific antibody to the subject.
Resumen de: AU2024306742A1
Described herein is certain quinoline carboxamides for use in the treatment of a myeloproliferative neoplasm (MPN). The quinoline carboxamides may more specifically be used in the treatment of advanced stages of MPN, including accelerated-phase MPN and secondary acute myeloid leukemia, i.e., acute myeloid leukemia evolving from an antecedent myeloproliferative neoplasm (post-MPN AML), optionally in combination with a further compound selected from a Janus kinase (JAK) inhibitor, a bromodomain and extra-terminal motif protein (BET) inhibitor, a B-cell lymphoma 2 (Bcl-2) inhibitor, and combinations thereof. Also included are pharmaceutical combinations of the quinoline carboxamides and second agents such as a BET inhibitor or a Bcl-2 inhibitor. Further included are certain quinoline carboxamides for use in combination with a BET inhibitor or a Bcl-2 inhibitor, in the treatment of a myeloproliferative neoplasm (MPN).
Resumen de: WO2025247377A1
The present application pertains to the field of medicinal chemistry and provides use of a sulfoximine compound for treating lymphoma. Specifically, the present application relates to use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating lymphoma.
Resumen de: WO2025250650A1
The present disclosure relates to crystalline forms of N-(l-(tert-butyl)-lH-pyrazol-4-yl)-2-( 4-((6-((methylsulfonyl)quinolin-4-yl)oxy)-3-methylphenyl)acetamide of formula (II) and crystalline forms of salts thereof. The compound of formula (II) is a RIPK2 inhibitor for the treatment of e.g. inflammatory diseases, autoimmune diseases, granulomatous disease, neurodegenerative diseases or cancer, and more specifically for the treatment of inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, rheumatoid arthritis, inflammatory arthritis, peritonitis, ischemia reperfusion injury in kidney transplant, non-alcohol steatohepatitis, alcohol steatohepatitis, insulin-resistant type 2 diabetes, allergic rhinitis, asthma, atopic dermatitis, Sjogren's syndrome, spondyloarthritis, ankylosing spondylitis, pemphigus vulgaris, idiopathic plasmacytic lymphadenopathy, atherosclerosis, myocardial infarction, thrombosis, alpha-synucleinopathy, Parkinson's disease, dementia with Lewy body, multiple system atrophy, Alzheimer's disease, amyotrophic lateral sclerosis, and chronic obstructive pulmonary disease
Resumen de: WO2025249980A1
The present invention relates to a therapy for preventing or treating lymphoma by administering poseltinib in combination with an immunomodulatory drug. In particular, the present invention achieves a synergistic effect on the prevention or treatment of diffuse large B-cell lymphoma and primary central nervous system lymphoma through the co-administration of poseltinib and lenalidomide.
Resumen de: US2025368655A1
Provided are compounds of Formula (I) wherein X is selected from the group of ethanyl, ethenyl, ethynyl, and triazinyl; R1 is selected from the group of R1 is selected from the group of alkyl, alkoxy, cycloalkyl, —CH2-cycloalkyl, —O— cycloalkyl, halogen, haloalkyl, OH, and CN; and R2 is a ring moiety selected from the group of imidazolyl, pyrazolyl, 1,2,3-triazolyl, thiazolyl, phenyl, and pyridinyl, each optionally substituted; for use as inhibitors against native BCR-ABL kinase protein and clinically important BCR-ABL mutations such as T315I, F317L, E255K and Y253F for the treatment of diseases that include chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), and acute myelogenous leukemia (AML).
Resumen de: WO2025248110A1
A method of treating BRAF mutant melanoma in a patient, including in a patient who is BRAF targeted therapy naïve, comprising administering a therapeutically effective amount of an oncolytic herpes simplex virus (HSV) and an anti-PD-1 antibody to the patient, wherein the oncolytic HSV comprises genes encoding (i) a glycoprotein from gibbon ape leukemia virus (GALV) from which the R peptide has been deleted (GALVR-) and (ii) GM-GSF.
Nº publicación: EP4656205A1 03/12/2025
Solicitante:
NIPPON ZENYAKU KOGYO CO LTD [JP]
Nippon Zenyaku Kogyo Co., Ltd
Resumen de: EP4656205A1
Provided is a method for treating canine B-cell lymphoma that is more effective than conventional methods. The method for treating canine B-cell lymphoma includes administering an anti-canine CD20 monoclonal antibody in combination with a chemotherapeutic agent, simultaneously or sequentially. The chemotherapeutic agent is one or more of vincristine, cyclophosphamide, prednisolone, and doxorubicin. The monoclonal antibody against canine CD20 and the chemotherapeutic agent are administered in combination, simultaneously or sequentially.
BOPI
Sede Electrónica
